<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53438">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02410512</url>
  </required_header>
  <id_info>
    <org_study_id>GO29674</org_study_id>
    <secondary_id>2015-000516-18</secondary_id>
    <nct_id>NCT02410512</nct_id>
  </id_info>
  <brief_title>A Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab With or Without Bevacizumab in Participants With Locally Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab With or Without Bevacizumab in Patients With Locally Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This Phase Ib, open-label, dose-escalation study will evaluate the safety, tolerability, and
      pharmacokinetics of the combination of MOXR0916 and Atezolizumab with or without bevacizumab
      in participants with locally advanced, recurrent, or metastatic incurable solid malignancy
      that has progressed after available standard therapy, or for which standard therapy has
      proven to be ineffective or intolerable, or is considered inappropriate; or for which a
      clinical trial of an investigational agent is a recognized standard of care.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicities (DLTs)</measure>
    <time_frame>up to 21 to 42 days after the first dose of study treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events graded per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0</measure>
    <time_frame>up to 90 days after the last dose of study treatment, or until the initiation of another systemic anti-cancer therapy, whichever occurs first</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters derived from serum MOXR0916 and serum atezolizumab concentrations: area under the concentration-time curve (AUC), maximum and minimum serum concentrations (Cmax and Cmin), clearance and volume of distribution at steady state</measure>
    <time_frame>Up to 120 days after the treatment discontinuation visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) determined as the time from first study treatment to death from any cause</measure>
    <time_frame>Assessed at regular intervals until death, up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-MOXR0916, anti-atezolizumab, and anti-bevacizumab antibodies</measure>
    <time_frame>Up to 120 days after the treatment discontinuation visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with objective response complete respons (CR) or partial response (PR) determined using RECIST v.1.1</measure>
    <time_frame>Assessed at regular intervals until disease progression, up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response determined using RECIST v.1.1</measure>
    <time_frame>Assessed at regular intervals until disease progression, up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) determined using RECIST v.1.1</measure>
    <time_frame>Assessed at regular intervals until disease progression, up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">762</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Doublet Dose Escalation: MOXR0916+Atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort of at least 3 participants each will be treated at escalating doses of MOXR0916 in combination with a fixed dose of Atezolizumab to determine the MTD or maximum administered dose (MAD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doublet Expansion: MOXR0916+Atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 250 to 620 participants will be enrolled in the expansion stage to better characterize the safety, tolerability, PK variability, biomarkers of anti-tumor activity, and preliminary efficacy of MOXR0916 + Atezolizumab in different cancer types.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triplet Dose Escalation: MOXR0916+Atezolizumab+Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort of at least 3 participants each will be treated at escalating doses of MOXR0916 in combination with fixed doses of atezolizumab and bevacizumab to determine the MTD or MAD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triplet Expansion: MOXR0916+Atezolizumab+Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 30 to 100 participants will be enrolled to better characterize the safety, tolerability, PK variability, biomarkers of anti-tumor activity, and preliminary efficacy of MOXR0916 + Atezolizumab + bevacizumab in different cancer types.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody</intervention_name>
    <description>Atezolizumab administered intravenously</description>
    <arm_group_label>Doublet Dose Escalation: MOXR0916+Atezolizumab</arm_group_label>
    <arm_group_label>Doublet Expansion: MOXR0916+Atezolizumab</arm_group_label>
    <arm_group_label>Triplet Dose Escalation: MOXR0916+Atezolizumab+Bevacizumab</arm_group_label>
    <arm_group_label>Triplet Expansion: MOXR0916+Atezolizumab+Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab, a recombinant humanised anti-VEGF (vascular endothelial growth factor) monoclonal antibody</intervention_name>
    <description>Bevacizumab administered intravenously</description>
    <arm_group_label>Triplet Dose Escalation: MOXR0916+Atezolizumab+Bevacizumab</arm_group_label>
    <arm_group_label>Triplet Expansion: MOXR0916+Atezolizumab+Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MOXR0916, a humanized agonist anti-OX40 monoclonal antibody</intervention_name>
    <description>MOXR0916 administered intravenously</description>
    <arm_group_label>Doublet Dose Escalation: MOXR0916+Atezolizumab</arm_group_label>
    <arm_group_label>Doublet Expansion: MOXR0916+Atezolizumab</arm_group_label>
    <arm_group_label>Triplet Dose Escalation: MOXR0916+Atezolizumab+Bevacizumab</arm_group_label>
    <arm_group_label>Triplet Expansion: MOXR0916+Atezolizumab+Bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 18 years of age or older

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Life expectancy of at least 12 weeks

          -  Adequate hematologic and end organ function

          -  Histologic documentation of locally advanced, recurrent or metastatic incurable solid
             malignancy that has progressed after available standard therapy, or for which
             standard therapy is ineffective, intolerable, or considered inappropriate; or for
             which a clinical trial of an investigational agent is recognized standard of care

          -  Tumor specimen availability

          -  Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST
             v1.1)

        Exclusion Criteria:

          -  Any anti-cancer therapy, whether investigational or approved, including chemotherapy,
             hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study
             treatment

          -  Malignancies other than disease under study within 5 years prior to Cycle 1, Day 1

          -  Primary central nervous system (CNS) malignancy, or untreated/active CNS metastase

          -  Leptomeningeal disease

          -  History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced),
             organizing pneumonia, or evidence of active pneumonitis on screening chest computed
             tomography (CT) scan; history of radiation pneumonitis in the radiation field
             (fibrosis) is permitted

          -  History of autoimmune disease

          -  Positive human immunodeficiency virus (HIV) test

          -  Active hepatitis B or C, or tuberculosis

          -  Severe infection within 4 weeks prior to randomization

          -  Prior allogenic bone marrow or solid organ transplantation

          -  Significant cardiovascular disease

          -  Known clinically significant liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: GO29674 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global.rochegenentechtrials@roche.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045-2517</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Villejuif CEDEX</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 1, 2016</lastchanged_date>
  <firstreceived_date>April 2, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Endothelial Growth Factors</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
